EGFR and non-small cell lung carcinoma: While osimertinib has proven effective for most patients with EGFR-mutated NSCLC in both clinical trials and real-world practice, cardiac toxicity remains a significant concern, particularly for those at higher risk, and requires careful monitoring and management [7,26,27].